Electrocardiographic safety of daily Hydroxychloroquine 400mg plus Azithromycin 250mg as an ambulatory treatment for COVID-19 patients in Cameroon.

Source: medRxiv

Abstract

Objective: To determine the early electrocardiographic changes in a cohort of ambulatory cameroonian COVID-19 patients treated with hydroxychloroquine and Azithromycin.

Design: Prospective study.

Setting: Treatment centres of the city of Yaounde, Cameroon, from May 7th to 24th 2020.

Participants: We enrolled 51 consecutive confirmed COVID-19 on RT-PCR who having mild forms of COVID-19 and treated by hydroxychloroquine 200mg twice daily during seven days plus Azithromycin 500 mg the first day and 250 mg the remaining 4 days as per national standard.

Main outcomes measures: The primary end-point was the change in QTc interval between day 0 (D0), day 3 (D3) and day 7 (D7). Secondary endpoints were changes in all other cardiac electrical conductivity patterns and the occurrence of clinical arrhythmic events during the course of treatment.

Results: The population (29 men and 22 women) was aged 39 +/- 11 years (range 17 to 61 years). Mean Tisdale score was 3.35 +/- 0.48. No significant change from baseline (D0) of QTc was observed at D7 (429 +/- 27 ms at D0 versus 396 +/- 26 ms at D7; p = 0.27). A reduction of heart rate was observed between the D0 and D7 (75 +/- 13 bpm versus 70 +/- 13 bpm, p = 0.02) with increased QRS duration between D0 and D7 (95 +/- 10 ms versus 102 +/- 17 ms, p = 0.004). No symptomatic arrhythmic events occurred during the treatment course.

Conclusions:

No life-threatening modifications of the QT interval was observed in non-severe COVID-19 patients treated ambulatory with hydroxychloroquine and azithromycin. Studies are needed in critical-ill and older patients.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the National Committee for Research Ethics in Human Health, Cameroon (Number 2020/05/1505/L/CNERSH/SP).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Related:

Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study

National Cancer Instititute: List of Active Clinical Trials Using Hydroxychloroquine for Cancer

A new study shows hydroxychloroquine would get out of hospital faster

Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/ azithromycin and other regimens in Marseille, France: A retrospective analysis

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

Trouble in Paradise Surrounding the use of Ivermectin

In nations around the world tension mounts between physicians and caregivers seeking to prescribe what they professionally deem as safe doses of ivermectin, as an off-label treatment for COVID-19 and national health authorities, which for the most part have all taken a hostile and oppositional position against the use of the drug.

Read More »

How Ivermectin became a Target for the ‘Fraud Detectives.’

And why is ivermectin being so negatively targeted by Big Tech and Big Media? One could argue conflict of interest plays a major role, given how intertwined they are with Big Pharma and the far-reaching grasp of the BMGF. A cheap and effective early treatment for Covid-19, like ivermectin, can be seen as a significant threat to the financial interests of those involved with Covid vaccines and expensive anti-viral drugs.

Read More »

Canada: Alberta Failing on COVID-19 Vaccines and Treatment

Numerous studies and clinical observation of thousands of patients has indicated that Ivermectin is highly effective in this regard. Even low dose studies that were designed to reach the conclusion that ivermectin was not effective found a signal that indicated that Ivermectin effectively interacted with the COVID virus molecule to prevent or lessen replication of the virus.”

Read More »